News | November 01, 2024
AstraZeneca China President currently under investigation
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
